Page last updated: 2024-11-12

xyloketal b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

xyloketal B: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

xyloketal B : A xyloketal with formula C20H26O5. It was initially isolated from the mangrove fungus Xylaria sp. from the South China sea coast. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID21776387
CHEMBL ID1170622
MeSH IDM0504576

Synonyms (3)

Synonym
(+/-)-xyloketal b
CHEMBL1170622
xyloketal b

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The oxidative endothelial dysfunction and decrease in nitric oxide (NO) bioavailability are critical for the development of atherosclerotic lesion."( Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice.
Cao, L; Huang, YY; Li, J; Li, M; Li, Q; Lin, YC; Liu, J; Pang, JY; Sun, FY; Sun, HS; Tan, HM; Wang, GL; Xie, Y; Yuan, F; Zhang, B; Zhang, Q; Zhao, LY, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" Mice were dosed with xyloketal B (5, 10 and 20 mg/kg/d) and atorvastatin (15 mg/kg/d) via intraperitoneal injection once daily for 40 days after being fed a high fat diet plus 10% high fructose liquid (HFD+HFL) for 8 weeks."( Xyloketal B Attenuates Fatty Acid-Induced Lipid Accumulation via the SREBP-1c Pathway in NAFLD Models.
Bei, Y; Huang, Y; Meng, T; Pang, J; Su, Z; Xiang, Q; Yang, H; Zhang, Q; Zhang, Y; Zuo, L, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID492791Vasorelaxant activity in Sprague-Dawley rat endothelium intact thoracic aortic rings assessed as inhibition of KPSS-induced contraction2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.
AID492798Antiangiogenic activity in zebrafish embryo after 72 hrs by microscopical analysis2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.
AID492797Antiangiogenic activity in zebrafish embryo at 100 uM after 72 hrs by microscopical analysis2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.
AID492792Vasorelaxant activity in Sprague-Dawley rat endothelium denuded thoracic aortic rings assessed as inhibition of KCL-induced contraction2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.
AID492793Protection against oxidatively modified low density lipoprotein-induced cell injury in HUVEC assessed as cell viability at 20 uM pretreated for 30 mins before oxLDL challenge measured after 24 hrs by MTT assay2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.
AID492796Cytotoxicity against HUVEC assessed as cell viability > 200 uM after 24 hrs by MTT assay2010Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
Design and synthesis of novel xyloketal derivatives and their vasorelaxing activities in rat thoracic aorta and angiogenic activities in zebrafish angiogenesis screen.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (13.04)29.6817
2010's17 (73.91)24.3611
2020's3 (13.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.35%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (95.65%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]